奥拉帕利在早期子宫内膜癌患者中的窗口机会试验:POLEN研究
POLEN窗口机会试验中,31例可手术1型子宫内膜癌患者术前接受奥拉帕利300mg每日两次口服至手术,中位暴露24天;组织样本显示cyclin D1显著抑制(p<0.01),Ki67和活化caspase-3无显著变化,PARP-1与cyclin D1正相关(rho=0.661,p=0.0001),ARID1A[-]肿瘤中两者均显著低于ARID1A[+]肿瘤(p=0.022和p=0.004)。
要点
- 奥拉帕利300mg每日两次术前给药可显著抑制1型子宫内膜癌cyclin D1表达(p<0.01)。
- PARP-1与cyclin D1正相关(rho=0.661,p=0.0001),ARID1A[-]肿瘤中两者均显著低于ARID1A[+]肿瘤。
- 血浆奥拉帕利浓度与GLUT1活性下降显著相关(r=-0.5885;p<0.05),毒性多为胃肠道和1–2级不良事件。
核心结论
- 奥拉帕利降低cyclin D1表达,且与PARP-1水平正相关,该效应在ARID1A缺陷肿瘤中更明显;奥拉帕利还诱导GLUT1血浆活性抑制。
研究设计与样本
- 窗口机会试验,可手术1型子宫内膜癌女性术前接受奥拉帕利口服片300mg每日两次,共28天,于基线和治疗完成时取组织样本,主要目的为评估奥拉帕利对子宫内膜癌的影响。
- 活性信号定义为细胞周期相关蛋白cyclin D1、Ki67和cleaved caspase-3表达的显著变化。
- 31例患者纳入生物标志物分析,奥拉帕利中位暴露时间为24天(1–39)。
主要发现
- cyclin D1显著抑制(p<0.01),Ki67和active caspase 3免疫染色无显著变化。
- PARP-1水平与cyclin D1水平正相关(rho=0.661,p=0.0001)。
- ARID1A[-]肿瘤中PARP-1和cyclin D1水平均显著低于ARID1A[+]肿瘤(p=0.022和p=0.004)。
- 血浆奥拉帕利浓度与GLUT1活性下降显著相关(r=-0.5885;p<0.05)。
- 药物相关毒性主要为胃肠道和1级或2级不良事件。
临床怎么用
- 作者认为,这些发现可能对预测哪些子宫内膜癌患者将从基于奥拉帕利的策略中获益具有值得注意的意义。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC). METHODS: In this window-of-opportunity trial, women with operable type 1 EC received olaparib oral tablets (300mg) twice daily for 28days before surgery. The primary objective was to evaluate the effects of olaparib on EC in tissue samples taken at baseline and at treatment completion. Signal of activity was defined as significant changes in the expression of the cell cycle-related proteins cyclin D1, Ki67, and cleaved caspase-3. RESULTS: A total of 31 patients were included in the biomarker analysis. The median time of olaparib exposure was 24 days (1-39). Significant inhibition was found for cyclin D1 (p < 0.01), but not for Ki67 and active caspase 3 immunostaining. PARP-1 levels positively correlated with cyclin D1 levels (rho = 0.661, p = 0.0001). Both PARP-1 and cyclin D1 levels were significantly lower (p = 0.022 and p = 0.004, respectively) in patients with ARID1A[-] tumors than ARID1A[+] tumors. A significant relationship between plasma olaparib concentrations and decreased GLUT1 activity was observed (r = -0.5885; p < 0.05). Drug-related toxicity consisted mostly of gastrointestinal and grade 1 or 2 adverse events. CONCLUSIONS: Olaparib reduced expression of cyclin D1, which positively correlated with PARP-1 levels. This effect was more evident in ARID1A-deficient tumors. Olaparib further induced inhibition of GLUT1 plasma activity. Our findings could have noteworthy implications in predicting which patients with EC would benefit from olaparib-based strategies.
引用
- Romero I, Rubio MJ, Medina M, et al. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study. Gynecol Oncol. 2020. PMID: 32988624. doi:10.1016/j.ygyno.2020.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。